Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Be the first to review this product

Availability: In stock

$2,995.00

Quick Overview

The Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Publication date Apr 2014
Publisher Current Partnering
Number of pages 1,114 including appendices
Report edition 5
Product code CP2054
ISBN n/a
Product type Research report
Available formats PDF, CD-ROM

* Required Fields

$2,995.00

The Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the asset purchase agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter asset purchase deals.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

                                

This report contains a comprehensive listing of all asset purchase deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.

                                                                                            

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.

                                                                

Chapter 3 provides an overview of the structure of asset purchase deals. The chapter includes numerous case studies to enable understanding of both pure asset purchase deals and multicomponent deals where asset purchase forms a part.

                       

Chapter 4 provides a review of the leading asset purchase deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

                      

Chapter 5 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of asset purchase deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of asset purchase deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of asset purchase deals signed and announced since 2009 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.

 

In addition the report includes a comprehensive listing of all asset purchase deals announced since 2009.

Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

           

The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2009.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.                         

 

Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:

 

  • In-depth understanding of asset purchase partnering deal trends since 2009
  • Insight into the terms included in an asset purchase agreement, together with real world clause examples
  •  Identify leading asset purchase deals by value since 2009
  • Identify the most active asset purchase dealmakers since 2009
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Full listing of  asset purchase deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
  • Comprehensive access to over 1,000 asset purchase deals entered into by the world’s biopharma companies, together with contract documents if available
  • Detailed access to actual asset purchase contracts entered into by the leading fifty big pharma and big biotech companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

TABLE OF CONTENTS

 

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in asset purchase dealmaking

 

2.1. Introduction

2.2. Types of assets purchased

2.3. Trends in asset purchase deals since 2009

2.3. Reasons for entering into asset purchase partnering deals

2.3.1. Business assets

2.3.2. Product assets

2.3.3. Royalty assets

2.3.4.Technology assets

2.4 The emergence of royalty asset purchase deals

2.4.1. Primary players in royalty asset purchase deals

2.4.2. Recent leading royalty asset purchase deals

2.4.3. The future of royalty asset purchase deals

2.5. The role of IP auction houses in asset purchase deals

2.5.1. Leading IP auction companies

2.6. The future of asset purchase agreements

 

Chapter 3 – Overview of asset purchase deal structure

 

3.1. Introduction

3.2. Asset purchase agreement structure

3.3. Example asset purchase agreements

3.3.1. Case study 1: Product asset: QLT – Valeant Pharmaceuticals

3.3.2. Case study 2: Business asset: Enzon Pharmaceuticals – Sigma-Tau

3.4. Anatomy of a royalty asset purchase agreement

3.5. Example royalty asset purchase agreements

3.5.1. Case study 3: Royalty asset: DRI Capital – NPS Pharmaceuticals

 

Chapter 4 – Leading asset purchase deals

 

4.1. Introduction

4.2. Top asset purchase deals by value

4.3. Most active asset purchase dealmakers

4.4. Big pharma asset purchase deal activity

4.5. Big biotech asset purchase deal activity

 

Chapter 5 – Big pharma asset purchase deals

 

5.1. Introduction

5.2. How to use asset purchase deals

5.3. Big pharma company asset purchase deal profiles

Abbott

Actavis

Allergan

Amgen

Astellas

AstraZeneca

Baxter International

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Daiichi Sankyo

Eli Lilly

Endo Pharmaceuticals

Forest Laboratories

Fresenius

Galderma

Gilead Sciences

GlaxoSmithKline

Grifols

Hospira

Johnson & Johnson

Kyowa Hakko Kirin

Lundbeck

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Mylan

Novartis

Novartis Consumer Health

Novo Nordisk

Pfizer

Roche

Sanofi

Servier

Shionogi

Shire

Stada

Takeda

Teva

UCB

Valeant

Warner Chilcott

 

Chapter 6 – Big biotech company asset purchase deals

 

6.1. Introduction

6.2. How to use big biotech partnering deals

6.3. Big biotech asset purchase partnering company profiles

3SBio

Acorda Therapeutics

Actelion

Alexion Pharmaceuticals

Alkermes

Biocon

Biogen Idec

BioMarin Pharmaceuticals

Cangene

Dendreon

Elan

Emergent BioSolutions

Galapagos

Ipsen

Optimer

PDL BioPharma

Questcor Pharmaceuticals

Regeneron Pharmaceuticals

SciClone Pharmaceuticals

Spectrum Pharmaceuticals

ViroPharma

 

Chapter 7 – Asset purchase contracts directory

 

7.1. Introduction

7.2. Company A-Z

7.3. By stage of development

 

Discovery

Formulation

Marketed

Phase I

Phase II

Phase III

Preclinical

Regulatory

 

7.4. By therapeutic target

 

Anaesthetics

Cardiovascular

Central Nervous System

Dental

Dermatology

Gastrointestinal

Genetic disorders

Genitourinary

Gynaecology

Hematology

Hospital care

Immunology

Infectives

Metabolic

Musculoskeletal

Obstetrics

Oncology

Ophthalmics

Orphan disease

Pediatrics

Psychiatry

Public health

Respiratory

Sexual health

 

7.5. By technology type

 

Analysis

Antibiotics

Assays

Bioinformatics

Biological compounds

Biomarkers

Biomaterials

Bioprocessing

Blood products

Cell culture

Clinical testing

Devices

Diagnostics

Discovery tools

Drug delivery

Enabling technology

Enviromental

Equipment

Facilities

Gene therapy

Genomics

Implant

Industrial chemicals

Nanotechnology

Natural product

Oligonucleotide

Peptides

Personalised medicine

Pharmacogenomics

Processes

Proteomics

Radio/Chemo-therapy

Recombinant DNA

Regenerative medicine

Research services

Research supplies

RNA therapeutics

Screening

Small molecules

Software tools

Stem cells

Vaccines

 

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

Order Form – Reports

Order Form – Reports

 

Appendices

 

Appendix 1: Asset purchase deals by Company A-Z

Appendix 2: Asset purchase deals by therapy area

Appendix 3: Asset purchase deals by stage of development at signing

Appendix 4: Asset purchase deals by technology type

 

TABLE OF FIGURES

 

Figure 1: Definition of assets purchased

Figure 2: Trends in asset purchase deal announcements, 2009-2014

Figure 3: Leading royalty asset investors

Figure 4: Recent leading royalty asset purchase agreements

Figure 5: Leading IP auction companies

Figure 6: Components of the asset purchase deal structure

Figure 7: Components of the royalty asset purchase deal structure

Figure 8: Top asset purchase deals by value since 2009

Figure 9: Most active asset purchase dealmakers 2009-2014

Figure 10: Bigpharma – top 50 – asset purchase deals 2009 to 2014

Figure 11: Big pharma asset purchase deal frequency - 2009 to 2014

Figure 12: Big biotech – top 50 – asset purchase deals 2009 to 2014

Figure 13: Big biotech asset purchase deal frequency - 2009 to 2014

 

 

 

Pricing options

  • $2,995: single-user
  • $4,495: multi-user
  • $8,995: single site license
  • $14,995: global site license

 

A full explanation of license type definitions can be found here.

 

An additional $500 per copy will be added for CD-ROM.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

Product Tags

Other people marked this product with these tags:

Use spaces to separate tags. Use single quotes (') for phrases.

Powered by LAMPsoft Ltd